OncoMatch

OncoMatch/Clinical Trials/NCT04787354

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Is NCT04787354 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Oxaliplatin and Capecitabine for gastric cancer.

Phase 3RecruitingHallym University Medical CenterNCT04787354Data as of Jun 2026Location: South Korea

Treatment: Oxaliplatin · CapecitabineThis study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8 cycles of XELOX).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

OxaliplatinCapecitabine

Cancer type

Gastric Cancer

Disease stage

Required: Stage II, III

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≥ 19

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: systemic chemotherapy

Prior systemic chemotherapy or radiation therapy for stomach cancer

Cannot have received: radiation therapy

Prior systemic chemotherapy or radiation therapy for stomach cancer

Lab requirements

Blood counts

ANC > 1,500/uL, Platelet >100,000/uL, Hb > 8.0 g/dL (patients with chronic anemia who require intermittent blood transfusions can also participate)

Kidney function

serum creatinine < 1.5 x upper limit of normal (ULN)

Liver function

serum total bilirubin ≤ 1.5 x ULN, ALT and AST ≤ 3 x ULN

Adequate marrow function (ANC > 1,500/uL, Platelet >100,000/uL, Hb > 8.0 g/dL, patients with chronic anemia who require intermittent blood transfusions can also participate in the study); Adequate renal function, with serum creatinine < 1.5 x upper limit of normal (ULN); Adequate hepatic function with serum total bilirubin ≤ 1.5 x ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT04787354 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage II or III is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify